Andrea Baldacci, Wolfgang Thormann
Index: J. Sep. Sci. 29(1) , 153-63, (2006)
Full Text: HTML
Lorazepam (LOR) is a 3-hydroxy-1,4-benzodiazepine that is chiral and undergoes enantiomerization at room temperature. In humans, about 75% of the administered dose of LOR is excreted in the urine as its 30-glucuronide. CE-MS with negative ESI was used to confirm the presence of LOR-30-glucuronide in urines that stemmed from a healthy individual who ingested 1 or 2 mg LOR, whereas free LOR could be detected in extracts prepared from enzymatically hydrolyzed urines. As the 30-glucuronidation reaction occurs at the chiral center of the molecule, two diastereoisomers can theoretically be formed, molecules that can no longer interconvert. The stereoselective formation of LOR glucuronides in humans and in vitro was investigated. MEKC analysis of extracts of the nonhydrolyzed urines suggested the presence of the two different LOR glucuronides in the urine. The formation of the same two diastereoisomers was also observed in vitro employing incubations of LOR with human liver microsomes in the presence of uridine 5'-diphospho-glucuronic acid as coenzyme. The absence of other coenzymes excluded the formation of phase I or other phase II metabolites of LOR. Both results revealed a stereoselectivity, one diastereoisomer being formed in a higher amount than the other. After enzymatic hydrolysis using beta-glucuronidase, these peaks could not be detected any more. Instead, LOR was monitored. Analysis of the extracts prepared from enzymatically hydrolyzed urines by MEKC in the presence of 2-hydroxypropyl-beta-CD revealed the enantiomerization process of LOR (observation of two peaks of equal magnitude connected with a plateau zone). The data presented provide for the first time the evidence of the stereoselectivity of the LOR glucuronidation in humans.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Lorazepam glucuronide
CAS:32781-79-6 |
C21H18Cl2N2O8 |
Commentary on: Dou C, Bournique J, Zinda M, Gnezda M, Nally ...
2002-03-01 [J. Forensic Sci. 47(2) , 427-8, (2002)] |
Population pharmacokinetics of lorazepam and midazolam and t...
2005-02-01 [Am. J. Kidney Dis. 45(2) , 360-71, (2005)] |
Biotransformation and excretion of lorazepam in patients wit...
1976-12-01 [Br. J. Clin. Pharmacol. 3(6) , 1033-9, (1976)] |
Quantitative assay of lorazepam and its metabolite glucuroni...
2006-02-13 [J. Pharm. Biomed. Anal. 40(2) , 389-96, (2006)] |
Effect of renal impairment and hemodialysis on lorazepam kin...
1984-05-01 [Clin. Pharmacol. Ther. 35(5) , 646-52, (1984)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved